Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
出版年份 2017 全文链接
标题
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
作者
关键词
-
出版物
OncoImmunology
Volume 7, Issue 3, Pages e1395127
出版商
Informa UK Limited
发表日期
2017-10-23
DOI
10.1080/2162402x.2017.1395127
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile
- (2017) Christine W. Bruggeman et al. JOURNAL OF IMMUNOLOGY
- Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer
- (2017) Antonio Rossi LANCET ONCOLOGY
- Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
- (2017) Hui Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Current progress in innovative engineered antibodies
- (2017) William R. Strohl Protein & Cell
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- IgG4 Characteristics and Functions in Cancer Immunity
- (2016) Silvia Crescioli et al. CURRENT ALLERGY AND ASTHMA REPORTS
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
- (2016) Richard J. Stopforth et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
- (2016) M. L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability
- (2016) Kevin J. Hamblett et al. MOLECULAR PHARMACEUTICS
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
- (2015) F. Donate et al. CLINICAL CANCER RESEARCH
- Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody–Drug Conjugates
- (2015) Brian Wiggins et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Macrophages are critical effectors of antibody therapies for cancer
- (2015) Kipp Weiskopf et al. mAbs
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
- (2014) Felix F. Schumacher et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- The Next Generation of Antibody Drug Conjugates
- (2014) Fiona Mack et al. SEMINARS IN ONCOLOGY
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Antibody-drug conjugates
- (2013) Alain Beck et al. mAbs
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Disulfide bond structures of IgG molecules
- (2012) Hongcheng Liu et al. mAbs
- Crystal structure of the human IgG4 CH3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange
- (2012) Anna M. Davies et al. MOLECULAR IMMUNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
- (2011) A Palumbo et al. BRITISH JOURNAL OF CANCER
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength
- (2011) A. F. Labrijn et al. JOURNAL OF IMMUNOLOGY
- Analytical methods for physicochemical characterization of antibody drug conjugates
- (2011) Aditya Wakankar et al. mAbs
- In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
- (2011) X. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Investigational antibody-drug conjugates for hematological malignancies
- (2010) Andrew G Polson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of EpCAM as a Molecular Target of Prostate Cancer Stroma
- (2009) Sumana Mukherjee et al. AMERICAN JOURNAL OF PATHOLOGY
- Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- (2009) D. Dornan et al. BLOOD
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Rab GTPases as coordinators of vesicle traffic
- (2009) Harald Stenmark NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Approved monoclonal antibodies for cancer therapy
- (2008) Michael Boyiadzis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-CD30 diabody-drug conjugates with potent antitumor activity
- (2008) K. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started